1 / 15

Introduction

Introduction. Russell Ellison, MD Chief Medical Officer Vice President, Medical Affairs Roche Laboratories, Inc. Accutane and Psychiatric Adverse Events. February 1998 bolded warning in label based on spontaneous reports of psychiatric events with Accutane: ie: an unconfirmed “signal”.

tania
Download Presentation

Introduction

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Introduction Russell Ellison, MDChief Medical OfficerVice President, Medical Affairs Roche Laboratories, Inc.

  2. Accutane and Psychiatric Adverse Events • February 1998 • bolded warning in label based on spontaneous reports of psychiatric events with Accutane: ie: an unconfirmed “signal”

  3. Accutane and Psychiatric Adverse Events • February 1998 to June 2000: • pharmacoepidemiological analysis of reports • clinical review of reports of suicides and related events • two retrospective epidemiologic cohorts [UKGPRD, Saskatchewan] • biological and clinical literature review

  4. Accutane and Psychiatric Adverse Events • This evidence does not support a causal association between Accutane and psychiatric events including suicide • Patients with acne, depending on age, gender, and prior history, may be at high risk for a concomitant psychiatric illness

  5. Agenda • IntroductionRussell Ellison, MD Chief Medical Officer, Vice President, Medical Affairs Roche Laboratories, Inc. • Clinical Context for Evaluation of Psychiatric Events and AccutaneDouglas Jacobs, MDAssociate Clinical Professor of Psychiatry Harvard Medical School • Pharmacoepidemiological Evaluation of Spontaneous ReportsRobert C. Nelson, PhDRCN Associates, Inc.

  6. Agenda • Epidemiological Studies and Biological Review John McLane, PhD Director/Medical Science and Safety Roche Laboratories, Inc. • Risk Management Russell Ellison, MD Vice President/Medical Affairs Roche Laboratories, Inc.

  7. Risk Management Options Russell Ellison, MDChief Medical OfficerVice President, Medical Affairs Roche Laboratories, Inc.

  8. Psychiatric Events Risk Management Issues • The evidence does not support a causal association of psychiatric illness with Accutane. Specific information related to possible risk of events beyond known risk factors for disease is lacking. • Patients with severe acne, depending on age, gender, and prior history, may be at high risk for a concomitant psychiatric illness

  9. Psychiatric Events Risk Management Issues • What information to convey, with what desired actions, to be taken by whom and in what circumstances? • e.g.: CME • Psychiatric disease as a concomitant illness: • alert the prescriber to this phenomenon • use the treatment venue as an opportunity for identifying possible problems • applicable to all high risk patients, include Accutane information

  10. Psychiatric Events Risk Management Issues • What information to convey, with what desired actions, to be taken by whom and in what circumstances? • e.g.: Labeling: • Professional: new Accutane data, symptoms, discontinuation, alert to comorbidity in all high risk patients • Patients: Accutane information, alert to symptoms, inform physician of previous history, alert to possibility of psychiatric illness irrespective of acne treatment

  11. Psychiatric Events Risk Management Issues • What information to convey, with what desired actions, to be taken by whom and in what circumstances? • e.g.: Labeling: informed consent • relative strength of causal association compared to other serious adverse events • what to inform patients about, for consent to treatment without a strong statement of cause, or estimates of risk

  12. Psychiatric Events Risk Management Issues • What information to convey, with what desired actions, to be taken by whom and in what circumstances? • e.g.: assessment before and during treatment • simple questionnaires (waiting room) available to identify the possibility of, psychiatric illness but not to confirm or rule out • for all high risk patients (part of dermatological assessment) • potential risk of conflict with time needed for pregnancy prevention in women...compliance?

  13. Psychiatric Events Risk Management Issues • Formal Studies: • Prospective clinical trial: • control group, hypothesis/sample size, blinding • Open cohort studies • matching cohorts unlikely • specificity of question, confidence in the answer • must be prospective

  14. Psychiatric Events Risk Management Issues • Retrospective epidemiologic cohort study: • available databases re: size, specific coding, population definitions • In vitro / in vivo preclinical studies: • specific models for specific psychiatric illness vs general CNS effects

  15. Conclusions • The evidence does not support a causal association between Accutane and psychiatric illness • Additional studies might somewhat clarify but not definitively resolve the issue • Much has been learned about psychiatric disease in acne patients…there is an opportunity to enhance the overall medical impact of the management of all acne patients

More Related